Thalia Therapeutics PLC
0GO
Company Profile
Business description
Thalia Therapeutics PLC is a specialist pharmaceutical company engaged in the development of mesoparticulate silica delivery systems to improve the cellular delivery and potency of vaccines. The company engaged in the development of a Liptide platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The Group operated in one business segment, that of the development and commercialisation of medicines via its delivery system called Nuvec and its liptide platform called ECP105.
Contact
2 Portman Street
LondonW1H 6DU
GBRT: +44 2046100714
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3
Stocks News & Analysis
stocks
ASX energy share undervalued ahead of earnings
Pricing strength outweighs temporary production headwinds.
stocks
Tesla: Reported China divestiture plan could clear path for SpaceX merger
Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.
stocks
This onetime AI market darling is now surprisingly undervalued
This AI leader qualifies as a GARP stock today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,127.40 | 18.70 | 0.21% |
| CAC 40 | 8,509.64 | 24.00 | 0.28% |
| DAX 40 | 25,629.24 | 17.21 | 0.07% |
| Dow JONES (US) | 52,485.03 | 276.97 | 0.53% |
| FTSE 100 | 10,868.05 | 29.22 | -0.27% |
| HKSE | 25,916.12 | 31.69 | 0.12% |
| NASDAQ | 25,373.85 | 251.68 | 1.00% |
| Nikkei 225 | 63,717.86 | 644.16 | -1.00% |
| NZX 50 Index | 13,744.18 | 44.90 | 0.33% |
| S&P 500 | 7,489.72 | 52.09 | 0.70% |
| S&P/ASX 200 | 8,963.40 | 14.40 | 0.16% |
| SSE Composite Index | 3,809.65 | 22.62 | -0.59% |